Attovia Therapeutics Clinical Trial Data
Attovia Therapeutics announced positive topline 12-week results from its Phase 1b study of ATTO-1310 in patients with chronic pruritus and high-itch atopic dermatitis. The data showed rapid and sustained itch relief with 82% of chronic pruritus patients achieving a clinically meaningful reduction in itch at Week 12, supporting the potential for quarterly maintenance dosing.
“The recently announced 12-week topline results from our ATTO-1310 Phase 1b trial exceeded our expectations, building on the compelling Week 4 findings and providing further evidence supporting our differentiated target product profile: rapid, deep, and durable itch relief, meaningful skin lesion improvements, the potential for quarterly dosing, and a favorable safety profile.”
Tao Fu, Founder and Chief Executive Officer of Attovia